|
1
|
Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients.
|
Cancer
|
2006
|
1.91
|
|
2
|
Panel of serum biomarkers for the diagnosis of lung cancer.
|
J Clin Oncol
|
2007
|
1.86
|
|
3
|
Identification and validation of a potential lung cancer serum biomarker detected by matrix-assisted laser desorption/ionization-time of flight spectra analysis.
|
Proteomics
|
2003
|
1.27
|
|
4
|
Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer.
|
Cancer
|
2007
|
1.11
|
|
5
|
Stable RNA interference-mediated suppression of cyclophilin A diminishes non-small-cell lung tumor growth in vivo.
|
Cancer Res
|
2005
|
1.03
|
|
6
|
Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer.
|
Lung Cancer
|
2004
|
1.01
|
|
7
|
Characterising phase variations in MALDI-TOF data and correcting them by peak alignment.
|
Cancer Inform
|
2005
|
0.95
|
|
8
|
Thermodynamic analysis of cyclosporin a binding to cyclophilin a in a lung tumor tissue lysate.
|
Anal Chem
|
2004
|
0.91
|
|
9
|
Biomarkers to help guide management of patients with pulmonary nodules.
|
Am J Respir Crit Care Med
|
2013
|
0.89
|
|
10
|
Analysis of human serum proteins by liquid phase isoelectric focusing and matrix-assisted laser desorption/ionization-mass spectrometry.
|
Proteomics
|
2003
|
0.86
|
|
11
|
Complement factor H autoantibodies are associated with early stage NSCLC.
|
Clin Cancer Res
|
2010
|
0.84
|
|
12
|
Throughput and efficiency of a mass spectrometry-based screening assay for protein-ligand binding detection.
|
J Am Soc Mass Spectrom
|
2008
|
0.81
|
|
13
|
The Association of Intratumoral Germinal Centers with early-stage non-small cell lung cancer.
|
J Thorac Oncol
|
2011
|
0.79
|
|
14
|
Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303).
|
Cancer
|
2011
|
0.78
|
|
15
|
Isolation of novel EGFR-specific VHH domains.
|
J Biomol Screen
|
2009
|
0.78
|
|
16
|
Discovery of novel cyclophilin A ligands using an H/D exchange- and mass spectrometry-based strategy.
|
J Biomol Screen
|
2010
|
0.76
|
|
17
|
Hydrogen/deuterium exchange- and protease digestion-based screening assay for protein-ligand binding detection.
|
Anal Chem
|
2009
|
0.75
|
|
18
|
Accentuation of differentially expressed proteins using phage technology.
|
Anal Biochem
|
2004
|
0.75
|